论文部分内容阅读
目的确保重庆市首例非血缘异基因外周血干细胞移植(URD-PBSCT)治疗慢性粒细胞白血病成功。方法对接受URD-PBSCT的慢性粒细胞白血病患者移植过程进行总结分析。结果患者造血重建迅速,中性粒细胞>0.5×109/L,血小板>20×109/L的时间分别为+13d、+16d,+17d患者的血型由O型转变为供者的B型,并经STR复检证实患者的性染色体由XY转为供者型的性染色体XX;移植过程中未见GVHD、VOD等严重并发症,骨髓细胞bcr/abl融合基因于+27d检查完全消失,+100d再次复查仍为阴性。结论重庆市首例URD-PBSCT治疗慢性粒细胞白血病患者获得圆满成功,URD-PBSCT可成为某些白血病得以根治的重要手段。
Objective To ensure that the first case of non-bloom allogeneic peripheral blood stem cell transplantation (URD-PBSCT) in Chongqing was successful in the treatment of chronic myelogenous leukemia. Methods The transplantation process of patients with chronic myelogenous leukemia receiving URD-PBSCT was analyzed. Results Hematopoietic reconstitution was rapid in patients with neutrophils >0.5×109/L, platelets >20×109/L for +13 days and +16 days, respectively. Patients with +17 days had blood type changed from O-type to donor-type B. The reexamination of the STR confirmed that the patient’s sex chromosome changed from XY to donor-type sex chromosome XX; GVHD, VOD and other serious complications were not seen during transplantation, and the bone marrow cell bcr/abl fusion gene disappeared completely at +27 days. The 100d review was still negative. Conclusion The first case of URD-PBSCT in Chongqing was successfully completed in patients with chronic myelogenous leukemia. URD-PBSCT can be an important means to cure certain leukemia.